Search research articles
Contact Us
Filters
Showing results (51-60 of 67) with videos related to
Page
of 7
Sort By:
European Urology Oncology
|
February 18, 2020
Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial
Rhonda L Bitting, Patrick Healy, Daniel J George, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 16, 2019
<sup>18</sup>F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab
Ilhan Lim, Maria Liza Lindenberg, Esther Mena, et al.
Journal for Immunotherapy of Cancer
|
April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal for Immunotherapy of Cancer
|
February 23, 2023
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
Monika Joshi, Leonard Tuanquin, Junjia Zhu, et al.
The Journal of Clinical Investigation
|
March 14, 2018
Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment
Jessica Wagner, C Leah Kline, Lanlan Zhou, et al.
Journal of Environmental Monitoring : JEM
|
December 22, 2009
The Brooklyn traffic real-time ambient pollutant penetration and environmental dispersion (B-TRAPPED) field study methodology
Jennifer Richmond-Bryant, Intaek Hahn, Christopher R Fortune, et al.
Lancet (London, England)
|
February 16, 2021
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
Sumanta K Pal, Catherine Tangen, Ian M Thompson, et al.
Journal for Immunotherapy of Cancer
|
March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma
Pedro Barata, Catherine Tangen, Melissa Plets, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 67) with videos related to
Sort By:
Page
of 7
European Urology Oncology
|
February 18, 2020
Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial
Rhonda L Bitting, Patrick Healy, Daniel J George, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 16, 2019
<sup>18</sup>F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab
Ilhan Lim, Maria Liza Lindenberg, Esther Mena, et al.
Journal for Immunotherapy of Cancer
|
April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal for Immunotherapy of Cancer
|
February 23, 2023
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
Monika Joshi, Leonard Tuanquin, Junjia Zhu, et al.
The Journal of Clinical Investigation
|
March 14, 2018
Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment
Jessica Wagner, C Leah Kline, Lanlan Zhou, et al.
Journal of Environmental Monitoring : JEM
|
December 22, 2009
The Brooklyn traffic real-time ambient pollutant penetration and environmental dispersion (B-TRAPPED) field study methodology
Jennifer Richmond-Bryant, Intaek Hahn, Christopher R Fortune, et al.
Lancet (London, England)
|
February 16, 2021
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
Sumanta K Pal, Catherine Tangen, Ian M Thompson, et al.
Journal for Immunotherapy of Cancer
|
March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma
Pedro Barata, Catherine Tangen, Melissa Plets, et al.
Page
of 7